Jakub Svoboda, MD, On Improving CR Rates With Next-generation CAR T Therapies

Video

The associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.

“A significant portion of patients who receive CAR Ts these days, the second-generation CAR T products, will not achieve long-term remissions. So, our project using the novel fourth generation, or armored CAR T, is part of the effort to really improve the outcomes and overcome some of the limitations that the current CART products have.”

huCART19-IL18 has demonstrated promising safety and efficacy in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) in a first-in-human trial (NCT04684563). huCART19-IL18 is a 4th generation, armored, autologous, anti-CD19 CAR and IL-18-expressing chimeric antigen receptor (CAR) T-cell product.

Data from the first-in-human study were presented by Jakub Svoboda, MD, associate professor of medicine, University of Pennsylvania, at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana. CGTLive spoke with Svoboda to learn more about unmet needs that remain in patients with NHL and CLL and how next-generation CAR T therapies, including huCART19-IL18, have advantages over older products that may help to address these issues.

REFERENCE
Svoboda J, Gerson J, Landsburg D, et al. Interleukin-18 secreting autologous anti-CD19 CAR T-cells (huCART19-IL18) in patients with non-Hodgkin lymphomas relapsed or refractory to prior CAR T-cell therapy. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans, Louisiana.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.